Danaher Corporation ( (DHR) ) has released its Q2 earnings. Here is a breakdown of the information Danaher Corporation presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Danaher Corporation is a global leader in life sciences and diagnostics, focusing on accelerating scientific and technological advancements to improve human health. The company has reported its second-quarter 2025 earnings, showcasing a modest revenue increase and strong cash flow, despite a challenging macroeconomic environment.
In the second quarter of 2025, Danaher Corporation reported net earnings of $555 million, translating to $0.77 per diluted share. The company’s revenues rose by 3.5% year-over-year, reaching $5.9 billion, while non-GAAP core revenue saw a 1.5% increase. Operating cash flow was robust at $1.3 billion, with free cash flow standing at $1.1 billion. The company’s Bioprocessing business continued to demonstrate strong growth, contributing significantly to the overall performance.
Key financial highlights include a non-GAAP adjusted diluted net earnings per share of $1.80 and a continued focus on disciplined cost management. Despite the fluid macro environment, Danaher remains confident in its ability to generate sustainable, long-term value for shareholders, driven by its diversified portfolio and strong financial profile.
Looking ahead, Danaher anticipates low-single-digit growth in non-GAAP core revenue for the third quarter of 2025. For the full year, the company maintains its expectation of approximately 3% growth in non-GAAP core revenue and has increased its full-year adjusted diluted net earnings per share guidance to a range of $7.70 to $7.80. This outlook reflects the company’s strategic focus on innovation and operational excellence.